Printer Friendly

MilliporeSigma partners with Baylor College of Medicine to advance vaccine manufacturing platform to fight COVID-19.

M2 PHARMA-May 28, 2020-MilliporeSigma partners with Baylor College of Medicine to advance vaccine manufacturing platform to fight COVID-19

(C)2020 M2 COMMUNICATIONS

Life science company MilliporeSigma said on Wednesday that it has extended its ongoing collaboration with Baylor College of Medicine to advance a manufacturing platform to develop a safe and effective COVID-19 vaccine and transition to Phase 1 clinical trials.

Using key learnings from their ongoing collaboration on a schistosomiasis vaccine, MilliporeSigma, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimising the production process to advance two COVID-19 vaccine candidates, including the CoV RBD219-N1 vaccine candidate expected to enter clinical trials later this year.

As part of the agreement, MilliporeSigma will help to accelerate their suitability for large-scale manufacturing. The collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs. The goal for the partnership is to develop a suitable manufacturing process and steps that would lead to a scale-up approach suitable for pilot and later industrial production.

Additionally, the partners will develop a new manufacturing platform for a second COVID-19 vaccine candidate to shorten the time to enter into Phase 1 clinical trials.

MilliporeSigma is the life science business of Merck KGaA (ETR:MRK).

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 28, 2020
Words:220
Previous Article:Athletico offers COVID-19 Recovery and Rehabilitation service.
Next Article:Maersk Drilling's Q1 2020 results affected by COVID-19 pandemic and falling oil prices.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters